Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | AACR 2023 highlights: why targeting KRAS is essential

Timothy Yap • 16 Apr 2023
AACR 2023
General

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, provides his highlights at the American Association for Cancer Research (AACR) Annual Meeting 2023, including a plenary session on targeting KRAS mutations. KRAS is highly important in signalling pathways, and multiple trials are underway assessing KRAS inhibitors. This interview took place at AACR 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Timothy Yap

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:41
Copanlisib and olaparib in PIK3CA hotspot, PTEN and DDR mutant tumors
Timothy Yap • 7 Apr 2024
2:31
PF-07220060 in HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy
Timothy Yap • 2 Jun 2023
1:24
A phase I/II trial to preliminary efficacy of BNT142 in prospectively confirmed CLDN6+ solid tumors
Timothy Yap • 2 Jun 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals